Expression of soluble TGF-β receptor II by recombinant Vaccinia virus enhances E7 specific immunotherapy of HPV16 tumors

Neoplasma

Volumn 58, Issue 3, 2011, Pages 181-188

  Zurkova, K ^a   Chlanda, P ^b   Samkova, Z ^a   Babiarova, K ^a   Kutinova, L ^a   Krystofova, J ^a   Hainz, P ^a   Nemeckova, S ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b MPI Neurobiology   (Germany)

Author keywords

E7; HPV16; Immunity; TGF beta; TGF beta receptor II; Tumor; Vaccinia virus

Indexed keywords

CHIMERIC PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN FC FRAGMENT; PROTEIN E7; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; PROTEIN SERINE THREONINE KINASE; RECOMBINANT VACCINE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOTHERAPY; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; VACCINIA VIRUS; VIRUS CARCINOGENESIS; VIRUS RECOMBINANT; ANIMAL; C57BL MOUSE; EXPERIMENTAL NEOPLASM; GENETICS; IMMUNIZATION; IMMUNOLOGY; T LYMPHOCYTE;

ANIMALS; FEMALE; HUMAN PAPILLOMAVIRUS 16; IMMUNIZATION; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 79961109224     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_03_181     Document Type: Article

References (45)

1. ZUR, HAUSEN H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009;384:260-265. doi:10.1016/j.virol.2008.11.046
2. SYRJANEN, S. Human papillomaviruses in head and neck carcinomas. N Engl J Med 2007;356:1993-1995. doi:10.1056/ NEJMe078004
3. Moscicki A. B., Palefsky J., Smith G., Siboshski S., Schoolnik G. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstet Gynecol 1993;82:578-585. doi:10.1097/00006250-199310000-00021
4. CHUA, K. L. and HJERPE, A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996;77:121-127. doi:10.1002/(SICI)1097-0142(19960101)77:1<121::AID-CNCR20>3.0.CO;2-6
5. HO, G. Y., BIERMAN, R., BEARDSLEY, L., CHANG, C. J., BURK, R. D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428. doi:10.1056/NEJM199802123380703
6. NAKAGAWA, M., VISCIDI, R., DESHMUKH, I., COSTA, M. D., PALEFSKY, J. M. et al. Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol 2002;9:877-882.
7. VON KNEBEL, DOEBERITZ M., OLTERSDORF, T., SCHWARZ, E., GISSMANN, L. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 1988;48:3780-3786.
8. STANLEY, M. A. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection. Expert Rev Vaccines 2003;2:381-389. doi:10.1586/14760584.2.3.381
9. BUTZ, K., DENK, C., ULLMANN, A., SCHEFFNER, M., HOPPE-SEYLER, F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci U S A 2000;97:6693-6697. doi:10.1073/pnas.110538897
10. STEELE, C., COWSERT, L. M., SHILLITOE, E. J. Effects of human papillomavirus type 18-specific antisense oligonucleotides on the transformed phenotype of human carcinoma cell lines. Cancer Res 1993;53:2330-2337.
11. MCKARNS, S. C., SCHWARTZ, R. H., KAMINSKI, N. E. Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol 2004;172:4275-4284. PMid:15034041
12. THOMAS, D. A. and MASSAGUE, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8:369-380. doi:10.1016/ j.ccr.2005.10.012
13. Ostroukhova, M., Seguin-Devaux, C., Oriss, T. B., Dixon-Mccarthy, B., Yang, L. et al. Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3. J Clin Invest 2004;114:28-38.
14. LIU, V. C., WONG, L. Y., JANG, T., SHAH, A. H., PARK, I. et al. Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007;178:2883-2892.
15. GHIO, M., CONTINI, P., NEGRINI, S., BOERO, S., MUSSO, A. et al. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of antitumor cytolytic activity. Eur J Immunol 2009;39:3459-3468. doi:10.1002/eji.200939728
16. GEISSMANN, F., REVY, P., REGNAULT, A., LEPELLETIER, Y., DY, M. et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999;162:4567-4575.
17. CHANG, H. L., GILLETT, N., FIGARI, I., LOPEZ, A. R., PALLADINO, M. A. et al. Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 1993;53:4391-4398.
18. Torre-Amione, G., Beauchamp, R. D., Koeppen, H., Park, B. H., Schreiber, H. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A 1990;87:1486-1490. doi:10.1073/pnas.87.4.1486
19. DASCH, J. R., PACE, D. R., WAEGELL, W., INENAGA, D., ELLINGSWORTH, L. Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 1989;142:1536-1541.
20. MAEDA, H. and SHIRAISHI, A. TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996;156:73-78.
21. JIA, Z. C., ZOU, L. Y., NI, B., WAN, Y., ZHOU, W. et al. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta. Cancer Immunol Immunother 2005;54:446-452. doi:10.1007/s00262-004-0619-4
22. WON, J., KIM, H., PARK, E. J., HONG, Y., KIM, S. J. et al. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy. Cancer Res 1999;59:1273-1277.
23. LIN, H. Y., MOUSTAKAS, A., KNAUS, P., WELLS, R. G., HENIS, Y. I. et al. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-beta receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-beta ligands. J Biol Chem 1995;270:2747-2754.
24. KOMESLI, S., VIVIEN, D., DUTARTRE, P. Chimeric extracellular domain type II transforming growth factor (TGF)-beta receptor fused to the Fc region of human immunoglobulin as a TGF-beta antagonist. Eur J Biochem 1998;254:505-513. doi:10.1046/j.1432-1327.1998.2540505.x
25. LO, K. M., SUDO, Y., CHEN, J., LI, Y., LAN, Y. et al. High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng 1998;11:495-500. doi:10.1093/ protein/11.6.495
26. Dallacqua, W. F., Kiener, P. A., Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal FC receptor (FcRn). J Biol Chem 2006;281: 23514-23524. doi:10.1074/jbc.M604292200 PMid:16793771
27. MURAOKA, R. S., DUMONT, N., RITTER, C. A., DUGGER, T. C., BRANTLEY, D. M. et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1551-1559.
28. MURAOKA, R. S., KOH, Y., ROEBUCK, L. R., SANDERS, M. E., BRANTLEY-SIEDERS, D. et al. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 2003;23:8691-8703. doi:10.1128/MCB.23.23.8691-8703.2003
29. ZHAO, X. P., HUANG, Y. Y., HUANG, Y., LEI, P., PENG, J. L. et al. Transforming growth factor-beta1 upregulates the expression of CXC chemokine receptor 4 (CXCR4) in human breast cancer MCF-7 cells. Acta Pharmacol Sin 2010;31:347-354. doi:10.1038/aps.2009.204
30. SALNIKOV, A. V., ROSWALL, P., SUNDBERG, C., GARDNER, H., HELDIN, N. E. et al. Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 2005;85:512-521. doi:10.1038/labinvest.3700252
31. NEMECKOVA, S., STRANSKA, R., SUBRTOVA, J., Kuti-Nova, L., Otahal, P. et al. Immune response to E7 protein of human papillomavirus type 16 anchored on the cell surface. Cancer Immunol Immunother 2002;51:111-119. doi:10.1007/ s00262-001-0261-3
32. KUTINOVA, L., NEMECKOVA, S., LUDVIKOVA, V., KUNKE, D., OTAVOVA, M. et al. Nektere problemy vyvoje vakcin zalozenych na rekombinantnim viru vakcinie. [Problems associated with the development of vaccines based on recombinant vaccinia virus]. Cas Lek Cesk 1992;131:770-773.
33. PERKUS, M. E., PANICALI, D., MERCER, S., PAOLETTI, E. Insertion and deletion mutants of vaccinia virus. Virology 1986;152:285-297. doi:10.1016/0042-6822(86)90132-7
34. MACKOVA, J., KUTINOVA, L., HAINZ, P., KRYSTOFOVA, J., SROLLER, V. et al. Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12. Int J Oncol 2004;24:1581-1588.
35. JOKLIK, W. K. The purification fo four strains of poxvirus. Virology 1962;18:9-18. doi:10.1016/0042-6822(62)90172-1
36. Lin, K. Y., Guarnieri, F. G., Staveley-Ocarroll, K. F., Levitsky, H. I., August, J. T. et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-26.
37. MICHL, J. Metabolism of cells in tissue culture in vitro. I. The influence of serum protein fractions on the growth of normal and neoplastic cells. Exp Cell Res 1961;23:324-330. doi:10.1016/0014-4827(61)90042-8
38. Zurkova, K., Hainz, P., Krystofova, J., Kutinova, L., Sanda, M. et al. Attenuation of vaccinia virus by the expression of human Flt3 ligand. Virol J 2010;7:109, doi:10.1186/1743-422X-7-109
39. ZURKOVA, K., BABIAROVA, K., HAINZ, P., KRYSTOFOVA, J., KUTINOVA, L. et al. The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector. Oncol Rep 2009;21:1335-1343.
40. LIN, H. Y. and WANG, X. F. Expression cloning of TGF-beta receptors. Mol Reprod Dev 1992;32:105-110. doi:10.1002/mrd.1080320205
41. XU, Q., WANG, S., XI, L., WU, S., CHEN, G. et al. Effects of human papillomavirus type 16 E7 protein on the growth of cervical carcinoma cells and immuno-escape through the TGF-beta1 signaling pathway. Gynecol Oncol 2006;101:132-139. doi:10.1016/j.ygyno.2005.09.051
42. KUTINOVA, L., LUDVIKOVA, V., SIMONOVA, V., Ota-Vova, M., KRYSTOFOVA, J. et al. Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them. Vaccine 1995;13:487-493. doi:10.1016/0264-410X(94)00019-J
43. KONTANI, K., KAJINO, K., HUANGI, C. L., FUJINO, S., TAGUCHI, O. et al. Spontaneous elicitation of potent antitumor immunity and eradication of established tumors by administration of DNA encoding soluble transforming growth factor-beta II receptor without active antigen-sensitization. Cancer Immunol Immunother 2006;55:579-587. doi:10.1007/s00262-005-0044-3
44. SPEHNER, D. and DRILLIEN, R. Extracellular vesicles containing virus-encoded membrane proteins are a byproduct of infection with modified vaccinia virus Ankara. Virus Res 2008;137:129-136. doi:10.1016/j.virusres.2008.07.003
45. CLAYTON, A., MITCHELL, J. P., COURT, J., MASON, M. D., TABI, Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 2007;67:7458-7466. doi:10.1158/0008-5472.CAN-06-3456